WO2005074961A1 - Agent luttant contre les reserves lipidiques de l'organisme - Google Patents

Agent luttant contre les reserves lipidiques de l'organisme Download PDF

Info

Publication number
WO2005074961A1
WO2005074961A1 PCT/JP2005/001883 JP2005001883W WO2005074961A1 WO 2005074961 A1 WO2005074961 A1 WO 2005074961A1 JP 2005001883 W JP2005001883 W JP 2005001883W WO 2005074961 A1 WO2005074961 A1 WO 2005074961A1
Authority
WO
WIPO (PCT)
Prior art keywords
body fat
hop
fat
regulator
weight
Prior art date
Application number
PCT/JP2005/001883
Other languages
English (en)
Japanese (ja)
Inventor
Toshiaki Waga
Yoko Akazome
Koichi Nakazato
Kouzen Sou
Atsushi Inoue
Yasuhiro Mizushima
Original Assignee
Asahi Breweries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Breweries, Ltd. filed Critical Asahi Breweries, Ltd.
Priority to JP2005517800A priority Critical patent/JPWO2005074961A1/ja
Publication of WO2005074961A1 publication Critical patent/WO2005074961A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Definitions

  • the present invention relates to a body fat regulator obtained from hops.
  • hop Human Lupulus
  • Cones Unfertilized hop female flowers (cones) are widely used throughout the world as a raw material for beer.
  • Hop flowers have yellow lupulin granules, which contain the resin that causes the bitterness of beer and the essential oils that give the aroma. Hops have an effect of imparting bitterness and aroma to beer, improving foam retention, and suppressing the growth of various bacteria, but are known to have many other medicinal effects. For example, it has been reported that it has allergic disease control, cancer prevention, anti-osteoporosis effect, diabetes complication prevention, antidepressant effect, etc. It is.
  • hop has an effect of suppressing weight gain in mice (Patent Document 1). It also reports that it has an inhibitory activity on lipase, an enzyme that degrades lipids, as an inhibitor of hop digestive enzymes (Patent Document 2).
  • Patent Document 1 Japanese Patent Application Laid-Open No. 2001-131080
  • Patent Document 2 Japanese Patent Application Laid-Open No. 2001-321166
  • the effect of the hops described in Patent Document 1 on suppressing weight gain in mice is not always limited to the reduction of body fat alone, but to the reduction of skeletal muscle mass and visceral weight. I cannot deny that I have lost more weight.
  • the inhibitory activity of lipase which is a lipid-degrading enzyme described in Patent Document 2 suppresses the absorption of lipid components in foods into the body, but the body fat is not a carbohydrate protein that can be separated from lipids alone.
  • lipase inhibition does not necessarily reduce body fat because it is easily biosynthesized. Therefore, it has not been reported that the polyphenol component contained in hops has the effect of reducing body fat and the effect of suppressing the accumulation of Z or body fat without reducing skeletal muscle mass and visceral weight. .
  • An object of the present invention is to develop a body fat regulator having an action of reducing body fat and an action of suppressing the accumulation of Z or body fat, without reducing skeletal muscle mass and visceral weight! In particular, to provide a body fat regulator derived from natural products.
  • the inventors of the present invention have conducted intensive studies on the above-mentioned problems, and as a result, from many natural products, polyphenols derived from hops, which are the raw materials for beer, have a structure that does not reduce the amount of skeletal muscle and visceral weight. They have found that they have an effect of suppressing fat reduction and accumulation, and based on this finding, they have completed the present invention.
  • the first aspect of the present invention relates to a body fat regulator comprising a hop-derived polyphenol as an active ingredient, which is effective for reducing body fat and suppressing Z or accumulation.
  • a second aspect of the present invention is that the hop-derived polyphenol has a high content of procyan-gin.
  • the present invention relates to the body fat regulator according to the first aspect.
  • a third aspect of the present invention relates to the body fat adjustor according to the second aspect, wherein the procyazine is a product obtained by polymerizing a catechin body.
  • a fourth aspect of the present invention relates to the body fat regulator according to any one of the first to third aspects, wherein the body fat is a visceral fat.
  • a fifth aspect of the present invention relates to the body fat regulator according to any one of the first to third aspects, wherein the body fat is subcutaneous fat.
  • a sixth aspect of the present invention relates to the body fat regulator according to any one of the first to third aspects, wherein the body fat is full fat.
  • a seventh aspect of the present invention relates to a food or drink containing the body fat regulator according to any one of the first to sixth aspects.
  • An eighth aspect of the present invention relates to a medicine containing the body fat regulator according to any one of the first to sixth aspects.
  • a ninth aspect of the present invention relates to a method for using a hop-derived polyphenol that is effective for reducing body fat and suppressing Z or accumulation for the production of a body fat regulator.
  • the hop-derived polyphenol (hereinafter referred to as "hop polyphenol”) in the present invention is, for example, extracted from hops with alcohol or the like, then clarified and passed through a styrenedibutylbenzene-based synthetic adsorption resin. It is obtained by adsorbing the polyphenol component by liquefaction, washing with water to completely remove saccharides and organic acids, and eluting with aqueous ethanol.
  • the hop polyphenol obtained in this way has an effect of reducing body fat and suppressing Z or accumulation, and thus has an effect of preventing diseases caused by obesity, maintaining health, etc. It is added to food and drink as a functional food or formulated as a pharmaceutical. It also has the function of enhancing muscle and muscle tension, preventing muscle attenuation and increasing muscle and muscle tension.
  • flavonoid glycosides such as high molecular weight procyan-dine, rutin, and isoquercitrin polymerized with a catechin body occupy most.
  • the "body fat regulator” refers to a substance that suppresses the accumulation of energy as body fat caused by excessive energy absorption, and uses this energy for activities such as muscles and internal organs. It refers to the action of converting into energy and reducing excess body fat, which regulates the amount of body fat and suppresses the increase. Therefore, the adjustment of body fat prevents unnecessary accumulation of body fat, which does not mean a dangerous action such as suppressing energy absorption more than necessary or reducing body fat and making it lean.
  • the body fat regulator of the present invention suppresses fat accumulation and acts to prevent obesity when administered in a growing condition, and when administered in a condition that is already obese, produces fat muscle and the like. Promotes conversion to protein and works to improve obesity.
  • muscle tension enhancement refers to an increase in muscle mass or an increase in muscle tension (force exerted by muscle).
  • Muscle attenuation refers to a decrease in muscle mass or a decrease in muscle tension, and includes muscle atrophy, muscle loss, and muscle fatigue.
  • the body fat regulator of the present invention can be made into a formulation together with commonly used carriers, auxiliaries, additives, and the like, and can be used as a pharmaceutical in a product such as an oral product according to a conventional method. Or mixed with food materials to produce food and drink.
  • administration as a medicament reduces body fat and eliminates obesity.
  • Ingestion as a food or drink can be used as a health food or functional food to prevent or maintain health due to obesity. Used.
  • the body fat regulator of the present invention contains hop polyphenol, which is derived from natural products, as an active ingredient, it has low side effects and is highly safe for the living body. In addition, it does not reduce skeletal muscle mass and visceral weight and is excellent in the action of reducing excess body fat and suppressing the accumulation of excess energy in the form of body fat. Products or pharmaceuticals have high safety and are very useful for preventing and improving obesity. Brief Description of Drawings
  • FIG. 1 is a diagram showing an increase in volume during a breeding period.
  • FIG. 2 is a view showing an average food consumption per day.
  • the hop which is a raw material of the present invention is a perennial plant of dioecious and dioecious species belonging to the family Araceae which is widely used as a raw material for beer throughout the world, and its unfertilized female flower has matured. It is a cone. This hop is used in the form of hop bracts, which are the source of bitterness of hop cones or beer. There is no problem using raw materials such as
  • Hop Power As a method for extracting polyphenol, a raw material such as hop bracts or hop cones or hop pellets containing hop bracts is mixed with water or a water such as alcohol, acetone, acetonitrile or the like of 50 v / v% or less. Extract with an aqueous solution of an organic solvent that is miscible with water.
  • a preferred example is water or ethanol containing 50 vZv% or less of water-containing ethanol.
  • the ratio between the raw material and the extraction solvent is preferably about 1:20 to 100 (weight ratio).
  • the extraction is preferably performed at about 195 ° C. under stirring for about 20 to 60 minutes.
  • An extract is obtained by filtration. If necessary, a filter aid such as perlite can be used.
  • the extract thus obtained is treated with a gel-type synthetic adsorbent and Z or an ultrafiltration membrane.
  • the gel-type synthetic adsorbent is adsorbed on the gel-type synthetic adsorbent, and the gel-type synthetic adsorbent is adsorbed with an aqueous solution of water or ethanol, preferably an ethanol solution of 11 OvZv%.
  • the adsorption step is a step of cooling the same extraction solution to a room temperature of about 15 to 30 ° C, passing the solution through a column filled with a gel-type synthetic adsorbent, and allowing the adsorbent to adsorb the body fat regulator. It is. At that time, if necessary, in order to increase the adsorption efficiency, it is desirable to reduce the organic solvent concentration of the extract to 10% or less in advance by concentration under reduced pressure or the like.
  • the material of the gel-type synthetic adsorbent include hydrophilic bur polymer, hydroxypropyl dextran, and styrylene benzene polymer.
  • the liquid passing time is preferably set so that the SV value is between 0.5 and 100.
  • the SV value referred to here is the following formula This is the value defined by 1.
  • the washing step is a step of washing the gel-type synthetic adsorbent holding the body fat regulator, and by this step, it is possible to remove contaminants and to further improve the purification degree of the body fat regulator.
  • a solvent used for washing water or an aqueous solution of 110 to 110 vZv% of ethanol is preferable, and it is preferable to wash by passing a solvent amount of about 110 to 10 times the amount of the resin.
  • the elution step is a step of desorbing and eluting the body fat adjuster from the gel-type synthetic adsorbent holding the body fat adjuster, and using a solvent used for elution such as hydrous alcohol, hydrous acetone, or hydrous acetonitrile. Particularly preferred examples include 30 vZv% or more of an aqueous ethanol solution or ethanol. It is desirable that the flow rate of the elution solvent be about 116 times the amount of the resin.
  • the obtained eluate is concentrated under reduced pressure, and the solvent is removed by a usual method such as freeze-drying or spray-drying to obtain a body fat regulator as a powder.
  • a solvent such as alcohol, acetone, or acetonitrile can be recovered and reused.
  • the body fat regulator obtained in this manner is an odorless flesh-colored, brown or pale yellow powder that has a slightly bitter taste, and the body fat regulator itself adsorbs to the gel-type synthetic adsorbent, and It is a polyphenol-like substance that does not permeate through an ultrafiltration membrane with a molecular weight cut-off of 1,000 or more.
  • the yield is 0.5-20. OwZw% in terms of hop bract weight, and 0.5% in terms of hop cone weight.
  • the gel-type synthetic adsorbent used can be repeatedly used after washing with an aqueous alcohol solution of 80 vZv% or more, an aqueous solution of sodium hydroxide of about 0.05 N, or the like.
  • the hop extract obtained in the above extraction step is treated with an ultrafiltration membrane having a molecular weight cut-off of 1,000 or more. If necessary, the extract may be concentrated under reduced pressure to reduce the concentration of the organic solvent.
  • the recovered organic solvent can be reused.
  • Materials for the membrane include cellulose, cellulose acetate, polysulfone, polypropylene, polyester, polyether sulfone, PVDF, etc. Any material can be used without particular limitation as long as it is usually used as a material for an ultrafiltration membrane. Also, if the molecular weight cut-off is 1,000 or more, it can be used without any problem.If a membrane with a high molecular weight cut-off is used, the yield will be extremely reduced.
  • an ultrafiltration membrane having a molecular weight cut-off of 10,000 to 20,000 is suitable because the time required is long.
  • the treatment is desirably performed until the amount of the remaining liquid is about lZio-lZioo at the start of the treatment, which is a force depending on the type of the extraction solvent and the ratio of the extraction solvent to the hop or hop bract.
  • the pressure at that time depends on the ultrafiltration membrane and the filtration device, but is preferably about 0.1 to 10. Okg / cm 2 . If necessary, once treated, dilute the remaining solution again with an appropriate solvent such as water, and re-process similarly to increase the degree of purification.
  • the solvent of the obtained upper remaining liquid is removed by a conventional method such as concentration, freeze-drying, or spray-drying to obtain a body fat regulator as a powder. Further, at the time of concentration under reduced pressure, a solvent such as alcohol, acetone, and acetonitrile can be recovered and reused.
  • the body fat regulator obtained in this manner is an odorless flesh-colored, brown or pale yellow powder that has a slightly bitter taste, and the body fat regulator itself is adsorbed by the gel-type synthetic adsorbent, and It is a polyphenol-like substance that does not permeate through an ultrafiltration membrane with a molecular weight cut-off of 1,000 or more.
  • the yield is 0.5-20. OwZw% in terms of hop bract weight, and 0.5% in terms of hop cone weight.
  • the active bodies of the body fat regulator obtained by the treatment with the gel-type synthetic adsorbent or the treatment with the ultrafiltration membrane are the same polyphenols, they are obtained by the treatment with the gel-type synthetic adsorbent.
  • the obtained body fat regulator can be dissolved in an appropriate solvent such as an aqueous alcohol solution and treated with an ultrafiltration membrane to further improve the degree of purification of the polyphenols as the active substance. The reverse is also possible.
  • a sufficiently useful body fat regulator can be obtained by a method using a gel-type synthetic adsorbent or a method using an ultrafiltration membrane alone.
  • the composition of the hop polyphenol obtained in the present invention is mainly composed of a polymer procyazine which is obtained by polymerizing a force techin body as a polymer polyphenol conjugate, and in addition, rutin, It also contains flavonoid glycosides such as isoquercitrin, and these components are effective in reducing body fat and suppressing accumulation. Furthermore, it is also effective in enhancing muscle and muscle tension.
  • the extracted polyphenol can be formulated together with commonly used carriers, auxiliaries, additives, etc., and can be made into an oral product according to a conventional method and used as a pharmaceutical. It can be mixed with ingredients to make food and drink.
  • Pharmaceuticals include tablets, capsules, granules, syrups and the like as oral preparations.
  • the force varies depending on the type of preparation, processing conditions, symptoms of the recipient, physical condition, height, weight, etc.
  • 0.1-80 mgZkg body weight is administered once or several times a day to achieve its effect sufficiently.
  • compositions containing the body fat regulator of the present invention can be prepared by a usual method using an inert, non-toxic, pharmaceutically suitable excipient or solvent, and a usual formulation such as a tablet. , Capsules, dragees, pills, tablets, fine granules, aerosols, syrups, emulsions, suspensions and solutions.
  • the therapeutically effective compound can be present in each case in a concentration of about 0.5 to 90% by weight, based on the total formulation, ie in an amount sufficient to achieve the above-mentioned effects.
  • Combinations are prepared, for example, by extending the active compound with solvents and / or excipients, if appropriate with emulsifiers and Z or suspending agents.
  • organic solvents can be used as auxiliary solvents, if appropriate.
  • Auxiliaries include, for example, water, non-toxic organic solvents such as paraffin (eg petroleum fractions), vegetable oils (eg peanut oil, sesame oil) and alcohols (eg ethanol and glycerin), excipients such as powders.
  • Natural minerals eg clay, alumina, talc and chalk
  • powdered synthetic minerals eg highly dispersible silica and silicates
  • sugars eg sucrose, ratatose and dextrose
  • emulsifiers eg polyoxyethylene fatty acid esters and Polyoxyethylene fatty alcohol ethers, alkyl sulfonates, aryl sulfonates
  • suspending agents eg, lignin sulfite waste liquor, methylcellulose, starch and polyvinylpyrrolidone
  • lubricants eg, magnesium stearate, talc, Stearic acid and sodium lauryl sulfate
  • Administration is performed in a usual manner, preferably by a force used orally or parenterally. . In that special case, it can also be carried out lingually or intravenously.
  • Injectable media is in particular water, which contains stabilizers and solubilizers customary for injection solutions and Z or buffers.
  • Such additives include, for example, tartrate buffer, borate buffer, ethanol, dimethyl sulfoxide, complexing agents (eg, ethylenediaminetetraacetic acid), high molecular weight polymers for adjusting viscosity (eg, liquid polyethylene oxide). ) Or a polyethylene derivative of hydrogenated sorbitan.
  • flavoring agents or coloring agents can be added to the active conjugates together with the above-mentioned auxiliary agents.
  • the food and drink containing the body fat regulator of the present invention may be in the form of the above-mentioned preparation, but may be in any food form such as solid food, semi-liquid food, gel food, and beverage.
  • any food form such as solid food, semi-liquid food, gel food, and beverage.
  • the required amount can be added to each food raw material and processed and manufactured by a general manufacturing method.
  • the preferred blending amount at this time is not particularly limited, but is 0.01 to 50% by weight, preferably 0.1 to 50% by weight in consideration of the characteristics, taste, intake, safety, economy, etc. of various foods and drinks. It is advisable to mix 1 to 10% by weight at the appropriate stage of the manufacturing process according to the purpose.
  • Foods and drinks containing the body fat regulator of the present invention are used for disease prevention, health maintenance, muscle strengthening, and the like, and the intake amount is not particularly limited, but is 0.1 per day. Ingested as processed goods containing 1,1Og, preferably 11Lg.
  • the body fat adjuster When adding a body fat adjuster to these foods and drinks, the body fat adjuster may be added in powder form, but preferably the body fat adjuster is added to a 12% aqueous solution or alcohol. An aqueous solution is preferably added as an alcohol solution.
  • the food or beverage containing the body fat accumulation inhibitor of the present invention may contain various components depending on the form of the food.
  • the various components referred to herein include starch, polysaccharides such as corn starch, dextrin, sucrose, glucose, fructose, maltose, stevioside, corn syrup, lactose, nicotinamide, calcium pantothenate, calcium salts, vitamins Group B, Aspar Tame, xylitol, sorbitol, sorbitan fatty acid ester, L-ascorbic acid, heart tocopherol, sodium erythorbic acid, citric acid, tartaric acid, malic acid, succinic acid, lactic acid, gum arabic, carrageenan, pectin, amino acids, yeast extract, glycerin Fatty acid esters, sucrose fatty acid esters, glycerin, propylene glycol, casein, gelatin, agar, pigments, fragrances, preservatives and the like.
  • polysaccharides such as corn starch, dextrin, sucrose, glucose, fructose,
  • styrene dibutyl benzene resin 80 ml of styrene dibutyl benzene resin
  • hop cones 20 g were ground in a mortar and extracted with 2 L of water at 95 ° C for 40 minutes with stirring. After filtration, the mixture was allowed to cool, and the extract was treated with an ultrafiltration membrane (XM50, manufactured by Amicon) having a molecular weight cut off of 50,000 at 1.0 kg / cm 2 at room temperature until the volume became 20 ml. The obtained upper residue was evaporated to dryness under reduced pressure to obtain 200 mg of a body fat regulator as a pale yellow powder having an odorless and slightly bitter taste. The yield from hops was 1%.
  • XM50 ultrafiltration membrane
  • hop bracts 20 g were extracted with 600 ml of a 50% aqueous ethanol solution at 80 ° C. for 40 minutes with stirring. After filtration, the extract was treated with an ultrafiltration membrane (YM10 manufactured by Amicon) having a cut-off molecular weight of 10,000 until it reached 60 ml at 3. Okg / cm 2 at room temperature. The obtained upper residue was freeze-dried to obtain 0.8 g of a body fat regulator as a pale yellow powder having an odorless and slightly bitter taste. The yield from hop bracts was 4%.
  • Figure 2 shows the daily food consumption of rats in each group during the breeding period.
  • the feed composition of the experimental animal feed (manufactured by Oriental Yeast Co., Ltd.) was based on the standard purified feed AIN-93M published in the US National Nutrition Research Institute (AIN) shown in Table 1.
  • the heart, liver, kidney, internal organs, soleus, soleus, plantaris, and gastrocnemius of the rats in the test and control groups were excised and weighed. It was measured. The results are shown in Table 2 in comparison with the control group. In addition, the tissue weight and visceral fat weight shown in Table 2 represent those corrected for the body weight after dissection.
  • Example 2 150 g of a body fat regulator of hop polyphenol obtained in Example 2, 90 g of ratatose and 17 g of corn starch were mixed, and the mixture was granulated together with a paste prepared from 70 g of corn starch. The obtained granules were mixed well with magnesium stearate lg, and the mixture was tableted with a tableting machine to produce 1,000 tablets.
  • Example 5 the tablet obtained in Example 5 was ingested by humans and subjected to a clinical test to examine the body fat reducing effect of the body fat regulator extracted from hop bracts.
  • the ingestible tablet is a test tablet (150 mg, 1 tablet) containing the body fat adjuster obtained in Example 5 and the body fat adjuster obtained in Comparative Example 1! Pana! ⁇ ⁇ ⁇ Control tablets (hereinafter referred to as placebo tablets).
  • placebo tablets the body fat adjuster obtained in Comparative Example 1! Pana! ⁇ ⁇ ⁇ Control tablets
  • the study was a parallel two-group comparative study employing a double-blind method by random assignment.
  • the study period was set for a total of 20 weeks: 4 weeks of pre-observation, 12 weeks of ingestion, and 4 weeks of post-observation after ingestion.
  • the test subjects were divided into two groups and consumed test tablets in the following manner.
  • Test group Each test tablet (150 mgZ, 1 tablet) was ingested before dinner (4 tablets each, total 4 tablets Z days).
  • Control group Placebo tablets (150 mgZ, 1 tablet) were each taken before dinner (4 tablets each, 4 tablets Z days). The subjects were instructed not to change their daily life, such as eating habits, smoking and exercise, except taking test tablets or placebo tablets every day.
  • the test was conducted twice in total, from the start of ingestion and 12 weeks after ingestion (end of ingestion). In principle, the test was performed within 4 days before and after the test. On the test day, the test was performed after at least 4 hours of fasting and 2 hours of fasting.
  • the waist was also measured. Measurement starts at the start of intake and intake 4 Weekly, 8 weeks after ingestion, 12 weeks after ingestion (end of ingestion), 5 times after the post-observation period.
  • test group showed a decreasing tendency 12 weeks after ingestion, while the control group showed an increasing tendency.
  • test group showed a decreasing tendency 12 weeks after ingestion, while the control group showed an increasing tendency.
  • hop polyphenol can be expected to have a cosmetic effect by tightening the waist and has an effect of reducing body fat.
  • Group Intake condition Item Ingestion start date Intake 4 weeks after ingestion 8 weeks after ingestion 1 week after ingestion After observation period Test tablet (Polywest size (cm) 85.7 ⁇ 6.5 86.3 ⁇ 6.3 85.5 ⁇ 6.2 85.8 ⁇ 6.1 85.0 ⁇ 6.2 Phenol Contained
  • Waist size ((cm) 0.0 ⁇ 0.0 0.6 ⁇ 2.8 -0.1 ⁇ 2.1 0.1 ⁇ 2.2-1 0.7 ⁇ 1.9 tablets) before dinner
  • Visceral fat area Visceral fat area after each intake period-Visceral fat area on the disclosure date of intake
  • Example 1 55.5 g of body fat regulator obtained in Example 1, 41. Og of crystalline cellulose, 2. Og of fine-grained diacid, 2. Og, and 1.5 g of sucrose fatty acid ester Total 100. Og Each of the above parts by weight Were uniformly mixed to obtain tablets and capsules according to a conventional method.
  • Example 2 The body fat regulator obtained in Example 1 (20. Og), starch (30.0 g), and lactose (50. Og) totaled 100. Og.
  • the above parts by weight were uniformly mixed to obtain powders and granules according to a conventional method.
  • Example 2 0.45 g of the body fat regulator obtained in Example 1, apple clear concentrated juice 15.0 g, fructose 5.0 g, citrate 0.2 g, flavor 2.0 g, pigment 0.15 g, sodium ascorbate 0. A beverage was produced with the composition of each of the above components in 05 g, 77.15 ml of water.

Abstract

L'intention est de fournir un agent luttant contre les réserves lipidiques de l'organisme obtenu à partir de houblon, c'est-à-dire un agent de lutte contre les réserves lipidiques de l'organisme trouvant son origine dans une matière naturelle et qui a des effets de réduction des réserves lipidiques de l'organisme et d'inhibition de l'accumulation de réserves lipidiques dans l'organisme sans abaisser la quantité de muscles squelettiques ou le poids des organes internes. Pour être plus précis, l'intention est d'obtenir du polyphénol à partir de houblon et d'utiliser celui-ci dans un agent de lutte contre les réserves lipidiques de l'organisme, un agent élevant la tension musculaire ou bien une boisson, un aliment et un médicament servant à réduire les réserves lipidiques de l'organisme, à inhiber l'accumulation de réserves lipidiques dans l'organisme et à élever la tension musculaire. A savoir, agent de lutte contre les réserves lipidiques de l'organisme contenant, comme ingrédient actif, du polyphénol et qui est efficace dans la réduction des réserves lipidiques de l'organisme et/ou l'inhibition de l'accumulation de réserves lipidiques dans l'organisme et boisson, aliment et médicament contenant celui-ci.
PCT/JP2005/001883 2004-02-10 2005-02-09 Agent luttant contre les reserves lipidiques de l'organisme WO2005074961A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2005517800A JPWO2005074961A1 (ja) 2004-02-10 2005-02-09 体脂肪調整剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004033904 2004-02-10
JP2004-033904 2004-02-10

Publications (1)

Publication Number Publication Date
WO2005074961A1 true WO2005074961A1 (fr) 2005-08-18

Family

ID=34836149

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/001883 WO2005074961A1 (fr) 2004-02-10 2005-02-09 Agent luttant contre les reserves lipidiques de l'organisme

Country Status (2)

Country Link
JP (1) JPWO2005074961A1 (fr)
WO (1) WO2005074961A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2057993A1 (fr) * 2006-08-31 2009-05-13 ASAHI BREWERIES, Ltd. Procede de production d'une preparation a base de houblon, preparation a base de houblon ainsi obtenue, agent anti-inflammatoire, aliment/boisson et produit pharmaceutique par voie orale
JP2009221116A (ja) * 2008-03-13 2009-10-01 Nagaoka Koryo Kk 天然素材の抗酸化作用および／またはリパーゼ阻害活性を増強させる方法、ならびに当該活性が増強された天然素材
JP2010037319A (ja) * 2008-08-08 2010-02-18 Shizuokaken Koritsu Daigaku Hojin 内臓脂肪蓄積抑制剤
JP2010173942A (ja) * 2009-01-27 2010-08-12 Sapporo Breweries Ltd 脂肪細胞分化抑制剤
JP2014097987A (ja) * 2013-12-17 2014-05-29 Shizuokaken Koritsu Daigaku Hojin 内臓脂肪蓄積抑制剤
JP2016188180A (ja) * 2015-03-30 2016-11-04 株式会社東洋新薬 特定成分含有組成物
JPWO2018117041A1 (ja) * 2016-12-20 2019-10-24 サントリーホールディングス株式会社 イソキサントフモールを含む脂質代謝促進用組成物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09291039A (ja) * 1995-12-26 1997-11-11 Suntory Ltd プロシアニジンを有効成分とする抗肥満剤
JP2001131080A (ja) * 1999-11-02 2001-05-15 Asahi Breweries Ltd ホップより得られる体重増加抑制物質
JP2001321166A (ja) * 2000-05-17 2001-11-20 Asahi Breweries Ltd ホップより得られるリパーゼ阻害物質
WO2002078726A1 (fr) * 2001-03-28 2002-10-10 Asahi Breweries,Ltd. Neutralisant de proteotoxines
JP2003095942A (ja) * 2001-09-21 2003-04-03 Ito En Ltd 脂肪細胞におけるグルコース取込阻害剤及びｇｌｕｔ４トランスロケーション抑制剤、筋肉細胞におけるグルコース取込活性化剤並びに脂肪軽減飲食物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09291039A (ja) * 1995-12-26 1997-11-11 Suntory Ltd プロシアニジンを有効成分とする抗肥満剤
JP2001131080A (ja) * 1999-11-02 2001-05-15 Asahi Breweries Ltd ホップより得られる体重増加抑制物質
JP2001321166A (ja) * 2000-05-17 2001-11-20 Asahi Breweries Ltd ホップより得られるリパーゼ阻害物質
WO2002078726A1 (fr) * 2001-03-28 2002-10-10 Asahi Breweries,Ltd. Neutralisant de proteotoxines
JP2003095942A (ja) * 2001-09-21 2003-04-03 Ito En Ltd 脂肪細胞におけるグルコース取込阻害剤及びｇｌｕｔ４トランスロケーション抑制剤、筋肉細胞におけるグルコース取込活性化剤並びに脂肪軽減飲食物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MURASE T. ET AL: "Cha Latekin Kohaigo Inryo no Kaihatsu-Cha Katekin no Taishibo Teigen Sayo.", BIO.CHEM., vol. 19, no. 1, 10 January 2004 (2004-01-10), pages 54 - 57, XP002991260 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2057993A1 (fr) * 2006-08-31 2009-05-13 ASAHI BREWERIES, Ltd. Procede de production d'une preparation a base de houblon, preparation a base de houblon ainsi obtenue, agent anti-inflammatoire, aliment/boisson et produit pharmaceutique par voie orale
EP2057993A4 (fr) * 2006-08-31 2014-03-12 Asahi Group Holdings Ltd Procede de production d'une preparation a base de houblon, preparation a base de houblon ainsi obtenue, agent anti-inflammatoire, aliment/boisson et produit pharmaceutique par voie orale
JP2009221116A (ja) * 2008-03-13 2009-10-01 Nagaoka Koryo Kk 天然素材の抗酸化作用および／またはリパーゼ阻害活性を増強させる方法、ならびに当該活性が増強された天然素材
JP2010037319A (ja) * 2008-08-08 2010-02-18 Shizuokaken Koritsu Daigaku Hojin 内臓脂肪蓄積抑制剤
JP2010173942A (ja) * 2009-01-27 2010-08-12 Sapporo Breweries Ltd 脂肪細胞分化抑制剤
JP2014097987A (ja) * 2013-12-17 2014-05-29 Shizuokaken Koritsu Daigaku Hojin 内臓脂肪蓄積抑制剤
JP2016188180A (ja) * 2015-03-30 2016-11-04 株式会社東洋新薬 特定成分含有組成物
JPWO2018117041A1 (ja) * 2016-12-20 2019-10-24 サントリーホールディングス株式会社 イソキサントフモールを含む脂質代謝促進用組成物
JP7058225B2 (ja) 2016-12-20 2022-04-21 サントリーホールディングス株式会社 イソキサントフモールを含む脂質代謝促進用組成物

Also Published As

Publication number Publication date
JPWO2005074961A1 (ja) 2007-09-13

Similar Documents

Publication Publication Date Title
US6294190B1 (en) Antiobestic agent containing procyanidin as the active ingredient
KR100795327B1 (ko) 근장력 증강제
JP4669920B2 (ja) 血糖上昇抑制且つ血圧上昇抑制作用を有する機能性素材
JPH09291039A (ja) プロシアニジンを有効成分とする抗肥満剤
US20100105766A1 (en) Composition for inhibition or prevention of bone density reduction
JPH09176019A (ja) 糖質分解消化酵素阻害剤並びにこれを配合した医薬品および飲食品
CN114502184A (zh) 防治冠状病毒感染的包括杜英萃取物的药物和食品组合物
WO2005074961A1 (fr) Agent luttant contre les reserves lipidiques de l'organisme
JP2005154432A (ja) ポリフェノールおよび／またはビタミンｃを含有するアセロラ処理物
JP2018070570A (ja) クロモジ抽出物
WO2004112510A1 (fr) Ameliorateur de physiologie de mouvement
KR100828069B1 (ko) 푸코잔틴 또는 이를 함유하는 해조류 추출물을 포함하는,지방간의 예방 또는 치료용 조성물
US9737583B2 (en) Composition for prevention or treatment of acute renal failure including herbal extract or fraction thereof as active ingredient
WO2005094858A1 (fr) Composition antidiabetique
JP2005170836A (ja) 海藻抽出物およびそれを含むリパーゼ阻害剤
KR102239066B1 (ko) 식물 추출물의 혼합물을 유효성분으로 함유하는 대사성 질환의 예방, 개선 또는 치료용 조성물
KR102470155B1 (ko) 용쑥 및 서양민들레를 포함하는 체중 또는 체지방 감소용 경구용 조성물
KR102439576B1 (ko) 뇌기능 개선용 영양전달체 조성물
JP2007070263A (ja) 糖尿病予防用組成物
KR102045847B1 (ko) 관능성 및 항당뇨 활성이 증대된 옥미수·호박 가미 경옥고
JP6131275B2 (ja) Ｉｇｆ−１産生促進剤
JP2006193501A (ja) アディポネクチン調節剤、それを含有する飲食品、食品添加物及び医薬
JP4722492B2 (ja) 鉄欠乏性貧血に伴う不定愁訴の予防又は改善剤。
KR102507569B1 (ko) 돌외잎 추출물의 제조방법 및 이에 따른 돌외잎 추출물
WO2022270616A1 (fr) Composition pour supprimer des lésions musculaires

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005517800

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase